If you're struggling to maintain your weight, there are options available that can help. Calocurb is a natural appetite suppressant that can help get you on track.

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Soy – and especially tofu – is “enjoying a new era of popularity” in the US thanks in part to its affordability, innovative ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The pharmaceutical industry came up with medicine that stops people from craving processed, addictive foods and the food industry is in a panic.

Dr. Will Bulsiewicz explains the importance of spacing meals apart to improve gut health, enhance digestion, and align with natural body rhythms.

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...